Cargando…

Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial

OBJECTIVES: To compared the effect of early antihypertensive treatment started within 24-48 h of stroke onset versus delaying treatment until day eight on reducing dependency or death. DESIGN: Multicentre, randomised, open label trial. SETTING: 106 hospitals in China between 13 June 2018 and 10 July...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Liping, Xie, Xuewei, Pan, Yuesong, Wang, Aili, Wei, Yufei, Liu, Jingyi, Nie, Ximing, Liu, Dacheng, Zhao, Zilin, Wang, Penglian, Shen, Suwen, Zhong, Chongke, Xu, Tan, Wang, Dali, Wang, Gui-Chun, Song, Denghua, Ma, Yunsheng, Zhao, Jinguo, Jiang, Yong, Jing, Jing, Meng, Xia, Obst, Katherine, Chen, Chung-Shiuan, Wang, David, Wang, Yilong, Zhang, Yonghong, Wang, Yongjun, He, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561001/
https://www.ncbi.nlm.nih.gov/pubmed/37813418
http://dx.doi.org/10.1136/bmj-2023-076448
_version_ 1785117829503123456
author Liu, Liping
Xie, Xuewei
Pan, Yuesong
Wang, Aili
Wei, Yufei
Liu, Jingyi
Nie, Ximing
Liu, Dacheng
Zhao, Zilin
Wang, Penglian
Shen, Suwen
Zhong, Chongke
Xu, Tan
Wang, Dali
Wang, Gui-Chun
Song, Denghua
Ma, Yunsheng
Zhao, Jinguo
Jiang, Yong
Jing, Jing
Meng, Xia
Obst, Katherine
Chen, Chung-Shiuan
Wang, David
Wang, Yilong
Zhang, Yonghong
Wang, Yongjun
He, Jiang
author_facet Liu, Liping
Xie, Xuewei
Pan, Yuesong
Wang, Aili
Wei, Yufei
Liu, Jingyi
Nie, Ximing
Liu, Dacheng
Zhao, Zilin
Wang, Penglian
Shen, Suwen
Zhong, Chongke
Xu, Tan
Wang, Dali
Wang, Gui-Chun
Song, Denghua
Ma, Yunsheng
Zhao, Jinguo
Jiang, Yong
Jing, Jing
Meng, Xia
Obst, Katherine
Chen, Chung-Shiuan
Wang, David
Wang, Yilong
Zhang, Yonghong
Wang, Yongjun
He, Jiang
author_sort Liu, Liping
collection PubMed
description OBJECTIVES: To compared the effect of early antihypertensive treatment started within 24-48 h of stroke onset versus delaying treatment until day eight on reducing dependency or death. DESIGN: Multicentre, randomised, open label trial. SETTING: 106 hospitals in China between 13 June 2018 and 10 July 2022. PARTICIPANTS: 4810 patients (≥40 years) were enrolled with acute ischaemic stroke within 24-48 h of symptom onset and elevated systolic blood pressure between 140 mm Hg and <220 mm Hg. INTERVENTIONS: Patients were randomly assigned to receive antihypertensive treatment immediately after randomisation (aimed at reducing systolic blood pressure by 10%-20% within the first 24 h and a mean blood pressure <140/90 mm Hg within seven days) or to discontinue antihypertensive medications for seven days if they were taking them, and then receive treatment on day 8 (aimed at achieving mean blood pressure <140/90 mm Hg). MAIN OUTCOME MEASURES: The primary outcome was the combination of functional dependency or death (modified Rankin scale score ≥3) at 90 days. Intention to treat analyses were conducted. RESULTS: 2413 patients were assigned to the early treatment group and 2397 were assigned to the delayed treatment group. Mean systolic blood pressure was reduced by 9.7% (from 162.9 mm Hg to 146.4 mm Hg) in the early treatment group and by 4.9% (from 162.8 mm Hg to 154.3 mm Hg) in the delayed treatment group within 24 h after randomisation (P for group difference <0.001). Mean systolic blood pressure was 139.1 mm Hg in the early treatment group and 150.9 mm Hg in the delayed treatment group on day seven (P for group difference <0.001). Additionally, 54.6% of patients in the early treatment group and 22.4% in the delayed treatment group had blood pressure of less than 140/90 mm Hg (P<0.001 for group difference) on day seven. At day 90, 289 trial participants (12.0%) in the early treatment group, compared with 250 (10.5%) in the delayed treatment group, had died or experienced a dependency (odds ratio 1.18 (95% confidence interval 0.98 to 1.41), P=0.08). No significant differences in recurrent stroke or adverse events were reported between the two groups. CONCLUSIONS: Among patients with mild-to-moderate acute ischaemic stroke and systolic blood pressure between 140 mm Hg and <220 mm Hg who did not receive intravenous thrombolytic treatment, early antihypertensive treatment did not reduce the odds of dependency or death at 90 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03479554
format Online
Article
Text
id pubmed-10561001
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-105610012023-10-10 Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial Liu, Liping Xie, Xuewei Pan, Yuesong Wang, Aili Wei, Yufei Liu, Jingyi Nie, Ximing Liu, Dacheng Zhao, Zilin Wang, Penglian Shen, Suwen Zhong, Chongke Xu, Tan Wang, Dali Wang, Gui-Chun Song, Denghua Ma, Yunsheng Zhao, Jinguo Jiang, Yong Jing, Jing Meng, Xia Obst, Katherine Chen, Chung-Shiuan Wang, David Wang, Yilong Zhang, Yonghong Wang, Yongjun He, Jiang BMJ Research OBJECTIVES: To compared the effect of early antihypertensive treatment started within 24-48 h of stroke onset versus delaying treatment until day eight on reducing dependency or death. DESIGN: Multicentre, randomised, open label trial. SETTING: 106 hospitals in China between 13 June 2018 and 10 July 2022. PARTICIPANTS: 4810 patients (≥40 years) were enrolled with acute ischaemic stroke within 24-48 h of symptom onset and elevated systolic blood pressure between 140 mm Hg and <220 mm Hg. INTERVENTIONS: Patients were randomly assigned to receive antihypertensive treatment immediately after randomisation (aimed at reducing systolic blood pressure by 10%-20% within the first 24 h and a mean blood pressure <140/90 mm Hg within seven days) or to discontinue antihypertensive medications for seven days if they were taking them, and then receive treatment on day 8 (aimed at achieving mean blood pressure <140/90 mm Hg). MAIN OUTCOME MEASURES: The primary outcome was the combination of functional dependency or death (modified Rankin scale score ≥3) at 90 days. Intention to treat analyses were conducted. RESULTS: 2413 patients were assigned to the early treatment group and 2397 were assigned to the delayed treatment group. Mean systolic blood pressure was reduced by 9.7% (from 162.9 mm Hg to 146.4 mm Hg) in the early treatment group and by 4.9% (from 162.8 mm Hg to 154.3 mm Hg) in the delayed treatment group within 24 h after randomisation (P for group difference <0.001). Mean systolic blood pressure was 139.1 mm Hg in the early treatment group and 150.9 mm Hg in the delayed treatment group on day seven (P for group difference <0.001). Additionally, 54.6% of patients in the early treatment group and 22.4% in the delayed treatment group had blood pressure of less than 140/90 mm Hg (P<0.001 for group difference) on day seven. At day 90, 289 trial participants (12.0%) in the early treatment group, compared with 250 (10.5%) in the delayed treatment group, had died or experienced a dependency (odds ratio 1.18 (95% confidence interval 0.98 to 1.41), P=0.08). No significant differences in recurrent stroke or adverse events were reported between the two groups. CONCLUSIONS: Among patients with mild-to-moderate acute ischaemic stroke and systolic blood pressure between 140 mm Hg and <220 mm Hg who did not receive intravenous thrombolytic treatment, early antihypertensive treatment did not reduce the odds of dependency or death at 90 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03479554 BMJ Publishing Group Ltd. 2023-10-09 /pmc/articles/PMC10561001/ /pubmed/37813418 http://dx.doi.org/10.1136/bmj-2023-076448 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
Liu, Liping
Xie, Xuewei
Pan, Yuesong
Wang, Aili
Wei, Yufei
Liu, Jingyi
Nie, Ximing
Liu, Dacheng
Zhao, Zilin
Wang, Penglian
Shen, Suwen
Zhong, Chongke
Xu, Tan
Wang, Dali
Wang, Gui-Chun
Song, Denghua
Ma, Yunsheng
Zhao, Jinguo
Jiang, Yong
Jing, Jing
Meng, Xia
Obst, Katherine
Chen, Chung-Shiuan
Wang, David
Wang, Yilong
Zhang, Yonghong
Wang, Yongjun
He, Jiang
Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial
title Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial
title_full Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial
title_fullStr Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial
title_full_unstemmed Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial
title_short Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial
title_sort early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561001/
https://www.ncbi.nlm.nih.gov/pubmed/37813418
http://dx.doi.org/10.1136/bmj-2023-076448
work_keys_str_mv AT liuliping earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT xiexuewei earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT panyuesong earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT wangaili earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT weiyufei earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT liujingyi earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT nieximing earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT liudacheng earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT zhaozilin earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT wangpenglian earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT shensuwen earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT zhongchongke earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT xutan earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT wangdali earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT wangguichun earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT songdenghua earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT mayunsheng earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT zhaojinguo earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT jiangyong earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT jingjing earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT mengxia earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT obstkatherine earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT chenchungshiuan earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT wangdavid earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT wangyilong earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT zhangyonghong earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT wangyongjun earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial
AT hejiang earlyversusdelayedantihypertensivetreatmentinpatientswithacuteischaemicstrokemulticentreopenlabelrandomisedcontrolledtrial